Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis
A live, multi-source view of Mirum Pharmaceuticals, Inc. (MIRM): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis.
Sector: Healthcare · Industry: Biotechnology · United States · 433 employees · mirumpharma.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Mirum Pharmaceuticals, Inc. (MIRM) had a market capitalization of $6.15B (forward -291.1) and a beta of 0.49; the shares traded in a 52-week range of $63.23 – $130.00 (30.4% over the year).
- Market cap
- $6.15B
- Enterprise value
- $6.88B
- Forward P/E
- -291.1
- EPS (trailing)
- $-14.08
- EPS (forward)
- $-0.35
- Payout ratio
- 0.0%
- 52-week range
- $63.23 – $130.00
- 52-week change
- 30.4%
- Beta
- 0.49
- Average volume
- 772,612
- Shares outstanding
- 61.0M
- Short % of float
- 13.96%
- Profit margin
- -139.2%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Mirum Pharmaceuticals, Inc. (MIRM) last closed at $100.61 (the last completed close before that scan).
Technicals at the scan: RSI 49 (neutral territory), price +1.5% versus its 20-day average, 20-day versus 50-day average spread -8.0%, MACD histogram 0.69.
Sentiment inputs: 0% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 82/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of MIRM; corporate insiders filed 0 buys and 9 sells (3 distinct filers, latest disclosure 2026-09-03). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Christopher Peetz (0B/5S), Jolanda Howe (0B/3S), Eric Bjerkholt (0B/1S). Who is trading what
RapidTradeView pick record
MIRM has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Mirum Pharmaceuticals, Inc. (MIRM) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MIRM.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.